What's Next for Gilead Sciences After Its Latest Clinical Success

What's Next for Gilead Sciences After Its Latest Clinical Success

Source: 
Motley Fool
snippet: 

Gilead Sciences (NASDAQ:GILD) delivered some good news for its investors on Tuesday. The big biotech, along with its smaller partner, Galapagos (NASDAQ:GLPG), announced positive results from a phase 3 clinical study evaluating filgotinib in treating rheumatoid arthritis. Gilead's share price got a nice bump from the news, while Galapagos stock skyrocketed.

The timing of the phase 3 update turned out to be really great. CEO John Milligan and CFO Robin Washington, along with John McHutchison, the biotech's chief scientific officer and head of research and development, fielded questions on Wednesday at the Morgan Stanley Healthcare Conference. Here are three things you'll want to know from what the executives said about what's next for Gilead after the latest clinical success.